Understanding Keytruda: The Immunotherapy Revolutionizing Cancer Treatment
Oncologists Explain Why They Prescribe Keytruda To Cancer Patients, When And How It Works
ndtv
Image: ndtv
Keytruda, an immunotherapy drug developed by Merck & Co., is transforming cancer treatment by enhancing the body's immune response against cancer cells. Approved for multiple cancer types in India, it is particularly effective in advanced stages and is prescribed based on specific biomarkers. Its unique mechanism allows for better patient outcomes with fewer side effects compared to traditional chemotherapy.
- 01Keytruda is an immunotherapy drug approved for various cancers, including melanoma and lung cancer.
- 02It works by blocking the PD-1 receptor, enabling T-cells to recognize and attack cancer cells.
- 03Oncologists prescribe Keytruda based on specific biomarkers present in tumors.
- 04The drug is associated with improved survival rates and quality of life for cancer patients.
- 05Keytruda is manufactured exclusively by Merck & Co., necessitating guidance from qualified oncologists.
Advertisement
In-Article Ad
Keytruda (pembrolizumab) is a groundbreaking immunotherapy drug that has revolutionized cancer treatment since its FDA approval in 2014 for advanced melanoma. Developed by Merck & Co., it is now approved in India for 14 indications across eight tumor types. Oncologists, like Dr. Pooja Babbar from Fortis Hospital Manesar, emphasize its effectiveness in treating various cancers, including lung, head and neck, and triple-negative breast cancer. Keytruda functions as an immune checkpoint inhibitor, targeting the PD-1 receptor on T-cells, which allows the immune system to better recognize and destroy cancer cells. This mechanism not only leads to enhanced patient outcomes but also minimizes the side effects typically associated with conventional chemotherapy. Oncologists prescribe Keytruda when specific biomarkers, such as PD-L1 expression or microsatellite instability, are present, particularly in advanced stages of cancer. The drug has shown promising results in improving long-term survival rates and reducing recurrence risks. However, it is crucial to note that Keytruda is produced by a single manufacturer, making it essential for patients to seek treatment under the guidance of qualified oncologists.
Advertisement
In-Article Ad
Keytruda's approval for multiple cancer types in India means that patients have access to a treatment that can significantly improve their chances of survival and quality of life.
Advertisement
In-Article Ad
Reader Poll
Do you believe immunotherapy like Keytruda should be more widely available for cancer patients?
Connecting to poll...
More about Merck & Co.
Read the original article
Visit the source for the complete story.





